Rationally-Designed Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies
AssigneeFox Chase Cancer Center
InventorsGregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
Life of this patent
Estimating the term…
Abstract
Methods for generating hybrid antibodies are provided.
Claims21
An isolated antibody which is immunologically specific for Mullerian Inhibiting Substance Type II Receptor (MISIIR), wherein said antibody comprises at least one region from Mullerian Inhibiting Substance (MIS) in place of at least one complementarity determining region (CDR).
A method for generating a hybrid antibody immunologically specific for a target protein, said method comprising replacing at least one complementarity determining region (CDR) of a first antibody with at least one amino acid sequence from a ligand of said target protein.
Dependencies are inferred from the claim text.